Opendata, web and dolomites

LymphoDrain SIGNED

First subcutaneous implant to treat lymphedema. Definitive solution for chronic lymphedema

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 LymphoDrain project word cloud

Explore the words cloud of the LymphoDrain project. It provides you a very rough idea of what is the project "LymphoDrain" about.

top3    federal    chuv    market    cover    received    models    15    lausanne    successfully    venture    fit    swartz    multidisciplinary    company    lymphatica    bioengineering    awards    created    micro    cti    international    prof    attracting    initial    care    underlying    replace    grant    population    patented    business    swiss    hospital    function    animal    team    clinical    positions    termis    unstoppable    epfl    kick    led    perspective    chronic    implantable    lymphatic    competition    accelerator    plan    designed    lymphedema    coupled    imagine    innovation    draining    treatments    lymphodrain    vessel    financial    invention    uses    melody    trajectory    treat    consciously    ait    treatment    segment    moment    vision    qualified    situation    off    cancer    million    valentina    presently    finalist    masschallenge    health    spin    winner    tested    lack    medtech    national    pump    marco    magnetically    suffer    2017    participated    catheters    university    people    laboratory    disruptive    triacca    switzerland    dr    2016    recognition    pisano    stage    disorders   

Project "LymphoDrain" data sheet

The following table provides information about the project.

Coordinator
LYMPHATICA MEDTECH SA 

Organization address
address: BATIMENT E EPFL INNOVATION PARK
city: LAUSANNE
postcode: 1015
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website http://www.lymphatica.ch
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-12-01   to  2018-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LYMPHATICA MEDTECH SA CH (LAUSANNE) coordinator 50˙000.00

Map

 Project objective

Lymphatica Medtech S.A. is a spin-off company created in 2017, from the Swiss Federal Institute of Technology in Lausanne (EPFL) and the Lausanne University Hospital (CHUV). It has designed and patented “LymphoDrain” a novel implantable system to replace the lymphatic vessel draining function to treat lymphatic disorders, in particular chronic lymphedema. It uses an underlying technology based on a magnetically controlled micro-pump coupled with draining catheters. LymphoDrain was developed by Dr. Marco Pisano and Dr. Valentina Triacca, in the Laboratory of Lymphatic and Cancer Bioengineering led by Prof. Melody Swartz. Since the initial invention, a multidisciplinary and highly qualified team has participated in the project bringing clinical perspective and attracting financial support from several organizations (CTI grant, FIT grant, AIT innovation grant). The recognition has been received at both national (Winner of Venture Kick stage I and II, Top3 at Venture Business Plan Competition 2016) and international level (finalist at Imagine IF Accelerator 2016, Top 2 at TERMIS-EU Business Plan Competition 2016). At the moment, Lymphatica is a finalist in the MassChallenge Switzerland Awards 2017 on a trajectory of unstoppable growth and recognition. LymphoDrain technology was consciously designed as an implantable system to cover the needs of a segment of the population, estimated at more than 15 million people in Europe and US who suffer of chronic lymphedema and presently lack effective treatments. The functionality of LymphoDrain has been successfully tested in large animal models. This vision positions LymphoDrain in a unique situation to access both the European and the US health care market as a disruptive technology in the treatment of lymphedema.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LYMPHODRAIN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LYMPHODRAIN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.1.;H2020-EU.2.3.1.)

WIMUACT (2017)

TECHNOLOGY FOR THE IMPROVEMENT OF SPORTS PERFORMANCE IN NON-PROFESSIONAL CONTEXTS

Read More  

REALM (2015)

A disruptive method to free physicians from Hospital Information Systems by generating fault free patient diagnostic documents in real-time using natural language

Read More  

Digiteal (2016)

Digiteal: European Payment and e-Invoicing platform

Read More